Objectif terraplasma GmbH has developed a small, portable and battery-operated device – plasma care – for the treatment of chronic and acute wounds. Besides ensuring a sufficient supply of oxygen, avoiding an infection is the most important criterion to enable fast and uncomplicated wound healing. Hard-to-heal wounds have a negative impact on patient wellbeing, are challenging for clinicians to manage and are costly to the health economy. plasmaCare incorporates its innovative cold plasma technology where plasma care will allow for a disruptive wound therapy that can save healthcare costs by facilitating early discharge from hospital, reducing wound dressing frequency (e.g. nursing time) and promote faster healing processes.terraplasma’s ambition is to reach the European market in 2020 with the innovation project boosting their efforts to fulfil this strategy: results of clinical studies on plasmaCare and their dissemination through the European network of skin specialists will be crucial to gain traction among patients, and healthcare providers in order to achieve the new product acceptance among customers and ultimately, their trust.Incorporated in Germany in 2011 and maintaining its core business in Europe with an annual balance sheet of ~ €1M and a staff headcount of 9, the company has evolved along the years from a pure R&D start-up into a commercial enterprise. The proposed work in Phase 1 of the SME instrument fits into the overall terraplasma plan to reach market by contributing the financial resources needed to plan a fast, sound and wider deployment of the plasmaCare solution and the market uptake. It will also allow the SME to accomplish key feasibility activities and reduce the business risks, such as business planning, customer identification and outreach, and stronger IP management strategy. Champ scientifique medical and health scienceshealth sciencesnursingnatural sciencesphysical sciencesplasma physicsmedical and health sciencesbasic medicineimmunology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Thème(s) EIC-SMEInst-2018-2020 - SME instrument Appel à propositions H2020-EIC-SMEInst-2018-2020 Voir d’autres projets de cet appel Sous appel H2020-SMEInst-2018-2020-1 Régime de financement SME-1 - SME instrument phase 1 Coordinateur TERRAPLASMA GMBH Contribution nette de l'UE € 50 000,00 Adresse LICHTENBERGSTRASSE 8 85748 GARCHING Allemagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Bayern Oberbayern München, Landkreis Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
